ReviewHeart (British Cardiac Society)2016
Cellular and molecular basis of RV hypertrophy in congenital heart disease.
Review in Heart (British Cardiac Society), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Immature and mature myocardium in the pathophysiology of hypertrophic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2026Review
- Article
- Adjunct cell therapy for hypoplastic left heart syndrome: therapeutic promise requires targeted design strategy.Stem cell research & therapy · 2025Article
- MicroRNA-34a-Dependent Attenuation of Angiogenesis in Right Ventricular Failure.Journal of the American Heart Association · 2024Article
- The right ventricle in tetralogy of Fallot: adaptation to sequential loading.Frontiers in pediatrics · 2023Review
- Cardiomyocyte Proliferation from Fetal- to Adult- and from Normal- to Hypertrophy and Failing Hearts.Biology · 2022Review
- Effect of cardioplegic arrest and reperfusion on left and right ventricular proteome/phosphoproteome in patients undergoing surgery for coronary or aortic valve disease.International journal of molecular medicine · 2022Article
- Accelerated Cardiac Aging in Patients With Congenital Heart Disease.Frontiers in cardiovascular medicine · 2022Review
- A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair.Signal transduction and targeted therapy · 2021Review
- Volume Load-Induced Right Ventricular Failure in Rats Is Not Associated With Myocardial Fibrosis.Frontiers in physiology · 2021Article
- Relationship Between the Eosinophil/Monocyte Ratio and Prognosis in Decompensated Heart Failure: A Retrospective Study.Journal of inflammation research · 2021Article
- The role of regenerative therapy in the treatment of right ventricular failure: a literature review.Stem cell research & therapy · 2020Review
- Article
- Gene-environment regulatory circuits of right ventricular pathology in tetralogy of fallot.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Metabolic Response to Stress by the Immature Right Ventricle Exposed to Chronic Pressure Overload.Journal of the American Heart Association · 2019Article
- Role of Inflammatory Cell Subtypes in Heart Failure.Journal of immunology research · 2019Review
- Pulmonary hypertension in congenital heart disease.Future cardiology · 2018Review
- Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism.JCI insight · 2018Article
- Review on Chamber-Specific Differences in Right and Left Heart Reactive Oxygen Species Handling.Frontiers in physiology · 2018Article
- Current Knowledge and Recent Advances of Right Ventricular Molecular Biology and Metabolism from Congenital Heart Disease to Chronic Pulmonary Hypertension.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
RV hypertrophy (RVH) is one of the triggers of RV failure in congenital heart disease (CHD). Therefore, improving our understanding of the cellular and molecular basis of this pathology will help in developing strategic therapeutic interventions to enhance patient benefit in the future. This review describes the potential mechanisms that underlie the transition from RVH to RV failure. In particular, it addresses structural and functional remodelling that encompass contractile dysfunction, metabolic changes, shifts in gene expression and extracellular matrix remodelling. Both ischaemic stress and reactive oxygen species production are implicated in triggering these changes and will be discussed. Finally, RV remodelling in response to various CHDs as well as the potential role of biomarkers will be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.